Racial, Ethnic Disparities Seen in Type 2 Diabetes After GDM
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, Sept. 8, 2023 -- Racial and ethnic inequities are considerable in type 2 diabetes mellitus (T2DM) after gestational diabetes mellitus (GDM), and characteristics at delivery partially explain these disparities, according to a study published online Sept. 11 in Obstetrics & Gynecology.
Teresa Janevic, Ph.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues estimated racial-ethnic disparities in T2DM following GDM in a retrospective cohort of 22,338 individuals with GDM.
The researchers found that the eight-year T2DM incidence was 11.7 percent overall and was 18.5, 16.8, 14.6, 5.5, and 5.4 percent in Black, South/Southeast Asian, Hispanic, East/Central Asian, and White individuals, respectively, with corresponding adjusted hazard ratios (95 percent confidence intervals) of 4.0 (2.4 to 3.9), 3.3 (2.7 to 4.2), 2.9 (2.4 to 3.3), and 1.0 (0.9 to 1.4) for each group compared with Whites. For Black, Hispanic, and South/Southeast Asian versus White disparities, clinical and social-structural pregnancy characteristics explained 9.3 and 23.8 percent, 31.2 and 24.7 percent, and 7.6 and 16.3 percent, respectively. Compared with Black, Hispanic, and South/Southeast Asian individuals, associations between education, Medicaid, WIC (Special Supplemental Nutrition Program for Women, Infants, and Children) participation, and body mass index with T2DM were more pronounced among White individuals.
"While racial and ethnic inequities are substantial in type 2 diabetes after GDM, the weak associations we see of common social or structural measures and body mass index in Black, Hispanic, and South and Southeast Asian individuals demonstrate the need for greater understanding of how structural racism influences postpartum cardiometabolic risk in these groups," Janevic said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.